International Journal of Hematology and Oncology 2021, Vol 31, Num 2 Page(s): 092-098
Factors Affecting Survival in Retroperitoneal Sarcomas Treated with Upfront Surgery: A Real-World Study by Turkish Oncology Group

Baran AKAGUNDUZ1, Tugba Akin TELLI2, Hasan Cagri YILDIRIM3, Sema Sezgin GOKSU4, Nazan DEMIR5, Emre HAFIZOGLU6, Muhammet OZER7, Gokcen Tugba CEVIK8, Abdullah SAKIN9, Sabin Goktas AYDIN10, Nilay Sengul SAMANCI11, Neslihan OZYURT12, Muhammed Mustafa ATCI13, Murat AYHAN14, Merve TURAN14, Nisanur SARIYAR2, Cengiz KARACIN15, Saadettin KILICKAP3, Semra PAYDAS16, Mutlu DOGAN17

1Erzincan Binali Yıldrıım University, Faculty of Medicine, Department of Medical Oncology, Erzincan, Turkey
2Marmara University, Faculty of Medicine, Department of Medical Oncology, Istanbul, Turkey
3Hacettepe University, Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey
4Akdeniz University, Faculty of Medicine, Department of Medical Oncology, Antalya, Turkey
5Eskisehir Osmangazi University, Faculty of Medicine, Department of Medical Oncology, Eskişehir, Turkey
6Ankara Bilkent State Hospital, Department of Medical Oncology, 06010, Ankara, Turkey
7Capital Health Regional Medical Center, Department of Internal Medicine, Trenton, NJ, USA
8Usak Research Hospital, Department of Medical Oncology, Turkey
9Yuzuncu Yil University Faculty of Medicine, Department of Medical Oncology, Van, Turkey
10Medipol Unıversity Faculty of Medicine, Department of Medical Oncology, Istanbul, Turkey
11Cerrahoasa University Faculty of Medicine, Department of Medical Oncology, Istanbul, Turkey
12Giresun Research Hospital, Department of Medical Oncology, Giresun, Turkey
13Prof. Dr. Cemil Taşçıoğlu State Hospital, Department of Medical Oncology, Istanbul, Turkey
14Kartal Lutfi Kırdar Research Hospital, Department of Medical Oncology, Istanbul, Turkey
15Recep Tayyip Erdogan University, Faculty of Medicine, Department of Medical Oncology, Rize, Turkey
16Cukurova University, Faculty of Medicine, Department of Medical Oncology, Adana, Turkey
17Ankara Abdurrahman Yurtaslan Oncology Research Hospital, Department of Medical Oncology, Ankara, TURKEY

Keywords: Survival, Retroperitoneal sarcoma, Adjuvant chemotherapy, Adjuvant radiotherapy, Surgery
Retroperitoneal sarcomas (RPS) account for approximately 15% of all soft tissue sarcomas (STS) and encompass a heterogeneous group of tumors with limited multimodality treatment options. Surgical resection with negative margins remains the standard primary treatment for patients with localized RPS. In this multicenter study, we aimed to demonstrate the real-world data on factors affecting survival in RPS treated with upfront surgery. We included a total of 197 patients who underwent curative-intent resection of a primary non-metastatic RPS between 2000-2020 at ten experienced medical oncology departments in Turkey. The median follow-up was 33 months. The median age of patients was 53 years, 57.4% of patients were female. Univariate analysis revealed that; tumor size, grade, necrosis, resection margin status, were factors affecting recurrence-free survival (RFS) (p= 0.002, p= 0.044, p= 0,024, p= 0.003 respectively). Age, tumor size, stage, resection margin status were factors affecting overall survival (OS) (p= 0.038, p= 0.001, p= 0.032, p< 0.001, respectively). In multivariate analysis, tumor size and resection margin status were independent factors affecting RFS and OS (all p-values < 0.05). Our study demonstrated that tumor size, and resection margin status were the main factors affecting survival in resected RFS. In comparison, adjuvant chemotherapy (CT), radiotherapy (RT), or multimodality treatment did not show OS and RFS advantages. We believe that advances in the molecular characterization of these tumors might help clinicians to detect the best candidates for adjuvant therapies in RPS.